Lucentis® receives positive opinion for patients with myopic choroidal neovascularization showing vision gains with only two injections
(Thomson Reuters ONE) -
Novartis International AG /
Lucentis® receives positive opinion for patients with myopic choroidal
neovascularization showing vision gains with only two injections
. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement.
* Lucentis recommended for approval in EU to treat patients with visual
impairment due to choroidal neovascularization secondary to pathologic
myopia
* Lucentis superior to current standard of care and improves mean visual
acuity by around 14 letters at one year with a median of a total of two
injections
* Untreated, 90 % of patients with myopic choroidal neovascularization suffer
severe visual loss
Basel, May 31, 2013 - Novartis has received a positive opinion from the
Committee for Medicinal Products for Human Use (CHMP) for Lucentis(®)
(ranibizumab) to treat patients with visual impairment due to choroidal
neovascularization (CNV) secondary to pathologic myopia (myopic CNV).
CNV is the most common vision-threatening complication of high myopia[1]. Myopic
CNV usually affects patients younger than 50 years old so any associated vision
loss can have not only a significant impact on their quality of life but also on
their productivity and to society[2]. In patients with untreated myopic CNV the
long-term prognosis is poor with approximately 90% of affected patients
developing severe vision loss after five years[3].
"Lucentis has already transformed the management of wet AMD, and we are very
hopeful that if Lucentis receives approval in a fourth major ocular indication
that patients with myopic CNV will benefit from this medicine," said Tim Wright,
Global Head of Development, Novartis Pharmaceuticals. "Currently, all we hope to
do for these patients is to stabilize vision and prevent further vision loss, so
a treatment with the long-term safety profile of Lucentis that actually improves
and maintains vision with just a few injections would be of great benefit."
The submission was supported by data from the Novartis-sponsored clinical trial,
RADIANCE, that showed Lucentis provides superior improvement in visual acuity
compared with the current licensed standard of care, Visudyne(®) (verteporfin
PDT), in patients with myopic CNV. These new data showed around 40% of Lucentis
treated patients compared with 15% of Visudyne treated patients gained 15 or
more letters of visual acuity at month three[4]. Mean visual acuity gains of
approximately 14 letters at one year were demonstrated with Lucentis; this was
with a median of 2.0 injections.
In this pivotal Phase III study patients were randomized to one of three
treatment arms: Lucentis treatment based on visual acuity stability (group 1) or
disease activity (group 2); or Visudyne treatment (group 3). Subjects randomized
to Visudyne could be given Lucentis after three months based on persistent
disease activity. The primary endpoint was Lucentis superiority to Visudyne
based on the mean visual acuity change from baseline to month three. Patients
were followed for twelve months.
Both the Lucentis treatment groups were statistically superior (p<0.00001) to
the Visudyne treatment group. Mean letter gains at month three from baseline in
the two Lucentis groups (groups 1 and 2) were 12.1 and 12.5 letters,
respectively, compared to a 1.4 letter gain in the Visudyne treatment arm (group
3). At twelve months, the mean letter gains from baseline were 13.8 (group
1), 14.4 (group 2) and 9.3 (group 3).
The safety profile of Lucentis was consistent with that observed in other
studies as well as real-world experience and no new ocular/non-ocular safety
risks were identified. The most common adverse events occurring in more than ten
percent of patients, at twelve months, were conjunctival hemorrhage (ocular) and
nasopharyngitis (non-ocular).
About Lucentis(®) (ranibizumab)
Lucentis is a humanized therapeutic antibody fragment designed to block all
biologically active forms of vascular endothelial cell growth factor-A (VEGF-A).
Increased levels of VEGF-A are seen in wet AMD and other ocular diseases such as
diabetic macular edema (DME) and retinal vein occlusion (RVO). Lucentis was
specifically designed for the eye, minimizing systemic exposure.
Lucentis is licensed for the treatment of wet AMD in more than 100 countries, in
more than 90 countries for the treatment of visual impairment due to DME and in
90 countries for visual impairment due to macular edema secondary to RVO,
including both branch- and central-RVO. In many countries, including those in
Europe, Lucentis has an individualized treatment regimen with the goal of
maximizing visual outcomes while minimizing under- or over-treating patients.
Lucentis has a well-established safety profile supported by 43 extensive
sponsored clinical studies and real-world experience. Its safety profile has
been well established in a clinical development program that enrolled more than
12,500 patients across indications and there is more than 1.7 million patient-
treatment years of exposure since its launch in the United States in 2006.
Lucentis was developed by Genentech and Novartis. Genentech has the commercial
rights to Lucentis in the United States. Novartis has exclusive rights in the
rest of the world. Lucentis is a registered trademark of Genentech Inc.
Novartis sponsors the eXcellence in Ophthalmology Vision Award (XOVA). XOVA is
an annual award launched in 2010 that provides funding to non-profit initiatives
and projects that will have a positive impact on improving the quality of eye
care and make a significant impact in addressing unmet needs in the fields of
ophthalmology and optometry.
Disclaimer
The foregoing release contains forward-looking statements that can be identified
by terminology such as "recommended," "hopeful," "will," "hope," "would be,"
"could," or similar expressions, or by express or implied discussions regarding
potential new indications or labeling for Lucentis or regarding potential future
revenues from Lucentis. You should not place undue reliance on these statements.
Such forward-looking statements reflect the current views of management
regarding future events, and involve known and unknown risks, uncertainties and
other factors that may cause actual results with Lucentis to be materially
different from any future results, performance or achievements expressed or
implied by such statements. There can be no guarantee that Lucentis will be
approved for any additional indications or labeling in any market. Nor can there
be any guarantee that Lucentis will achieve any particular levels of revenue in
the future. In particular, management's expectations regarding Lucentis could be
affected by, among other things, unexpected clinical trial results, including
unexpected new clinical data and unexpected additional analysis of existing
clinical data; unexpected regulatory actions or delays or government regulation
generally; competition in general; government, industry and general public
pricing pressures; the company's ability to obtain or maintain patent or other
proprietary intellectual property protection; unexpected manufacturing issues;
the impact that the foregoing factors could have on the values attributed to the
Novartis Group's assets and liabilities as recorded in the Group's consolidated
balance sheet, and other risks and factors referred to in Novartis AG's current
Form 20-F on file with the US Securities and Exchange Commission. Should one or
more of these risks or uncertainties materialize, or should underlying
assumptions prove incorrect, actual results may vary materially from those
anticipated, believed, estimated or expected. Novartis is providing the
information in this press release as of this date and does not undertake any
obligation to update any forward-looking statements contained in this press
release as a result of new information, future events or otherwise.
About Novartis
Novartis provides innovative healthcare solutions that address the evolving
needs of patients and societies. Headquartered in Basel, Switzerland, Novartis
offers a diversified portfolio to best meet these needs: innovative medicines,
eye care, cost-saving generic pharmaceuticals, preventive vaccines and
diagnostic tools, over-the-counter and animal health products. Novartis is the
only global company with leading positions in these areas. In 2012, the Group
achieved net sales of USD 56.7 billion, while R&D throughout the Group amounted
to approximately USD 9.3 billion (USD 9.1 billion excluding impairment and
amortization charges). Novartis Group companies employ approximately 129,000
full-time-equivalent associates and operate in more than 140 countries around
the world. For more information, please visit http://www.novartis.com.
Novartis is on Twitter. Sign up to follow (at)Novartis at
http://twitter.com/novartis.
References
1. Neelam K et al. Choroidal neovascularization in pathological myopia. Prog
Retin Eye Res 2012;31:495-525.
2. Rose K et al. Quality of life in myopia. Br J Ophthalmol 2000;84:1031-1034.
3. Yoshida T et al. Myopic choroidal neovascularization: a 10-year follow-up.
Ophthalmology 2003;110:1297-1305.
4. Wolf S et al. Ranibizumab vs verteporfin PDT for choroidal neovascularization
secondary to pathologic myopia: a Phase III study. Asia Pacific Academy of
Ophthalmology 2013.
# # #
Novartis Media Relations
Central media line : +41 61 324 2200
Eric Althoff Mark Grossien
Novartis Global Media Relations Novartis Pharmaceuticals Communications
+41 61 324 7999 (direct) +41 61 696 5780 (direct)
+41 79 593 4202 (mobile) +41 79 489 7688 (mobile)
eric.althoff(at)novartis.com mark.grossien(at)novartis.com
e-mail: media.relations(at)novartis.com
For Novartis multimedia content, please visit www.thenewsmarket.com/Novartis
For questions about the site or required registration, please contact:
journalisthelp(at)thenewsmarket.com.
Novartis Investor Relations
Central phone: +41 61 324 7944
Samir Shah +41 61 324 7944 North America:
Pierre-Michel Bringer +41 61 324 1065 Stephen Rubino +1 862 778 8301
Thomas Hungerbuehler +41 61 324 8425 Jill Pozarek +1 212 830 2445
Isabella Zinck +41 61 324 7188 Edwin Valeriano +1 212 830 2456
e-mail: investor.relations(at)novartis.com e-mail:
investor.relations(at)novartis.com
Media release (PDF):
http://hugin.info/134323/R/1706060/564467.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Novartis International AG via Thomson Reuters ONE
[HUG#1706060]
Unternehmensinformation / Kurzprofil:
Datum: 31.05.2013 - 13:21 Uhr
Sprache: Deutsch
News-ID 265250
Anzahl Zeichen: 12537
contact information:
Town:
Basel
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 161 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Lucentis® receives positive opinion for patients with myopic choroidal neovascularization showing vision gains with only two injections"
steht unter der journalistisch-redaktionellen Verantwortung von
Novartis International AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
